Fort Worth-based NanOlogy, LLC, a clinical-stage oncology company, has named veteran biopharma executive David Arthur as its new chief executive officer.

Arthur becomes the company’s chief executive as NanOlogy moves toward later-stage development and commercialization. Founder H. Paul Dorman remains chairman.…

The post NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones appeared first on Dallas Innovates.

UTA and the Texas A&M Engineering Experiment Station have opened a new biomanufacturing training and research hub at Pegasus Park focused on workforce training and early-stage biotech development.

The National Center for Therapeutics Manufacturing satellite campus, or NCTM2, offers hands-on training, state-of-the-art lab space and support for early-stage biotech companies.…

The post UTA, Texas A&M TEES Open Biomanufacturing Training and Research Hub at Pegasus Park appeared first on Dallas Innovates.

“The pace of change has never been greater.”

Cait Brumme
CEO
MassChallenge
… on why MassChallenge’s INNOVATE ’25 focuses on what’s next

That’s the thinking behind INNOVATE ’25: DFW Setting the Pace, the annual day-long symposium MassChallenge is bringing to Dallas on Thursday.…

The post The Last Word: MassChallenge CEO on INNOVATE ’25 and Looking Ahead at Forces Shaping Economies appeared first on Dallas Innovates.

Colossal Biosciences, the Dallas-based de-extinction startup working to bring back the woolly mammoth, Tasmanian tiger, and dodo bird, just made its first acquisition. It has acquired Viagen Pets and Equine, a Texas company that’s been cloning animals commercially since 2002.

The pairing brings together a $10.3 billion decacorn known for seemingly impossible science with a company that’s cloned 15 species, including endangered ones, and runs a commercial pet cloning business with a five-to-seven month waitlist.…

The post Dallas Decacorn Colossal Buys Viagen, a Texas Pioneer in Animal Cloning appeared first on Dallas Innovates.

Palo Alto, California-based Overture Life—the company behind “the world’s first babies born from robotic fertilization and robotic egg freezing”—has opened its U.S. clinical operations headquarters in Dallas  The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos, with machine-learning support.…

The post Overture Life Opens Its First U.S. IVF Robotics Clinical Lab and Operations Hub in Dallas appeared first on Dallas Innovates.

Lantern Pharma Inc. (Nasdaq: LTRN) said it plans to launch a clinical trial in early 2026 for a rare pediatric brain cancer, following what it called an “optimistic meeting” with the U.S. Food and Drug Administration.

In an announcement, the Dallas-based biotech said the planned Phase 1b/2 trial will evaluate its drug candidate LP-184/STAR-001 in children with central nervous system cancers, including atypical teratoid rhabdoid tumors—a fast-growing brain tumor that primarily affects young children.…

The post Lantern Pharma Preps 2026 Trial for Rare Pediatric Brain Cancer After FDA Guidance appeared first on Dallas Innovates.

When scientists grow and engineer cells for research, those cells can be accidentally mislabeled, contaminated, or even copied without permission. The consequences are costly: industry-wide, such errors lead to billions of dollars in losses each year and put critical discoveries at risk.…

The post UT Dallas Researchers ‘Barcode’ Engineered Cells with Patent-Pending Tech to Protect Biotech IP appeared first on Dallas Innovates.

With biotechnology investment still mired in a post-pandemic bear market, Texas biotechs are working to stay competitive after a sharp decrease in funding last year. But new state laws, the rise of artificial intelligence, and the prospect of federal initiatives, including regulatory reform, have some feeling more optimistic about the sector’s future.…

The post ‘The Model is Broken’: From North Texas, a National Call to Action for Biotech’s Future appeared first on Dallas Innovates.

Dallas-based Women In Bio Executive Director Gina Ford has been named as the organization’s first-ever chief executive officer, taking on an expanded role as both CEO and a member of the board of directors.

“Women are excelling in the life sciences and biotech industries—earning more degrees, driving financial performance, and advancing innovation across the field,” Dianne Keen-Kim, board chair and president of Pittsburgh, Pennsylvania-based Women In Bio, said in a statement.…

The post Women In Bio Names Its Executive Director as CEO, Board Member appeared first on Dallas Innovates.

“They said it couldn’t be done without genetic testing.”

—Tech FW

.…The Fort Worth nonprofit marked Nanoscope Therapeutics’  just-watch-us moment on LinkedIn, as the local biotech made history with the first-ever FDA biologics application for a gene-agnostic therapy that could help blind patients see again.…

The post The Last Word: Tech FW on How Nanoscope’s ‘Watch Us’ Moment Could Help Blind Patients See Again appeared first on Dallas Innovates.

CAGE Bio—a San Carlos, California-based clinical-stage biotech startup developing therapies for immune-mediated dermatological conditions—has relocated its Fort Worth office to BioLabs at Pegasus Park in Dallas. 

The company has taken a private lab suite in BioLabs’ 37,000 square foot facility.

Founded in 2016, CAGE Bio’s platform technology was invented by bioengineer Samir Mitragotri.…

The post CAGE Bio Relocates Fort Worth Office to BioLabs at Pegasus Park in Dallas appeared first on Dallas Innovates.

Months after turning its dire wolf de-extinction into a moonshot milestone, Colossal Biosciences is going bigger—and taller. The company, now Texas’ first decacorn with a valuation of more than $10 billion, has unveiled plans to recreate New Zealand’s giant moa: a 12-foot-tall, 500-pound flightless bird that’s been extinct for six centuries.…

The post Colossal Biosciences Takes On De‑Extinction of New Zealand’s 12‑Foot Moa After Dire Wolf Milestone appeared first on Dallas Innovates.

Dallas-based biotech company Signify Bio has launched with an oversubscribed $15 million initial financing round. The round was led by by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, a subsidiary of Danaher Corporation, Eli Lilly and Co.,…

The post Dallas’ Signify Bio Launches With Oversubscribed $15M Financing, Partnership With UT Southwestern appeared first on Dallas Innovates.

Veteran biopharma executive Eric Matthews has joined Irving-based Caris Life Sciences, a leading next-generation AI TechBio company and precision medicine pioneer, as chief business officer, biopharma business development.

In that role, Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris’ expanding portfolio of biopharma partnerships, Caris said.…

The post Caris Life Sciences Appoints Chief Business Officer, Biopharma Business Development appeared first on Dallas Innovates.

GenrAb, a biotechnology startup based at Pegasus Park in Dallas, has raised $5.6 million in seed funding to advance what it describes as a “first-in-class” therapy designed to help brain cells survive—using naturally occurring antibodies discovered in the spinal fluid of patients with neurological disease.…

The post UT Southwestern Spinout Emerges From Stealth With $5.6M to Push ‘First in Class’ Neuroprotective Therapy Into the Clinic appeared first on Dallas Innovates.

Irving-based next-generation AI techbio company Caris Life Sciences has closed a growth capital funding round of $168 million. With the new funding, Caris said it has raised $1.86 billion in capital since 2018.

Braidwell LP, a Stamford, Connecticut-based life science-focused investment firm and an existing investor, led the financing with participation from new investors Perceptive Advisors, Woodline and Ghisallo, along with additional new investors.…

The post Caris Life Sciences Raises $168M in Private Capital to Expand Platform appeared first on Dallas Innovates.

A sound not heard on Earth for more than 12,500 years is back. The howl of a dire wolf—extinct since before recorded history and known to most through “Game of Thrones”—has returned, according to Dallas-based Colossal Biosciences.

The company announced today the successful birth of three dire wolves, calling it the world’s first true de-extinction.…

The post Hear the Howl: Dallas De‑Extinction Company Colossal Biosciences Brings Back Dire Wolf Using Ancient DNA appeared first on Dallas Innovates.

According to Alzheimer’s Disease International, someone develops dementia every three seconds, globally. The organization estimates that seventy-eight million people will be living with this brain disease by 2030. 

Studies and even clinical trials are happening, but history shows research has not been equal between men and women. …

The post This Biopharma Trio Is Tackling the Blind Spots in Women’s Health appeared first on Dallas Innovates.

Dallas-based Colossal Biosciences is making history—again.

The world’s first de-extinction company, founded in 2021 by entrepreneur Ben Lamm and renowned Harvard geneticist George Church, has become Texas’ first “decacorn”—startup speak for a private company valued at more than $10 billion—after securing $200 million in new funding.…

The post Dallas’ Colossal Biosciences Becomes Texas’ First Decacorn, Securing $10.2B Valuation With Series C Funding appeared first on Dallas Innovates.

France-based global animal health provider Virbac, whose North American headquarters is in Westlake, has collaborated with biotech company Emmyon to introduce URSOLYX Soft Chews, a first-in-its-class muscle support product for dogs that features ursolic acid, which targets mRNA expression in skeletal muscle.…

The post Muscling Up Dogs: Westlake-Based Virbac NA Launches Soft Chews That Improve Canine Mobility appeared first on Dallas Innovates.